NASDAQ · BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) · SMALL CAP
Outlook Therapeutics, Inc. OTLK
11 fiscal years on record · USD · FY2025 reported
SEC FILINGS ONLY
Revenue · FY2025
$1.4M
EPS · FY25
$-1.79
Dividend / sh · FY25
—
Payout · FY25
—
ROE · FY25
—
Net margin · FY25
-4416.2%
Dividend coverage
—
Advertisement
AdSense · Leaderboard 728×90320×100
Result
USD 1.4M
Revenue, FY2025 · full 11-year series below
Revenue
Net income
The company lost 4416 cents on every revenue dollar this year.
Per share
USD -1.79
Diluted EPS, FY2025
EPS
The company pays no cash dividend.
Profitability
—
Return on equity, FY2025
ROE
Operating margin-4744.3%
Net margin-4416.2%
Return on assets-263.4%
Returned to shareholders
—
returned in FY2025 · dividends + net buybacks
Dividends paid—
Net buybacks—
Share of profit—
Consecutive raises—
Growth
—
revenue, compounded over five years
CAGR
3 yrs
5 yrs
10 yrs
15 yrs
Revenue
−12.2%
Compound annual rates per period — left blank where the series crosses a loss.
Share base
0.05B
Shares outstanding, FY2025
Change, 5 years—
Change, 10 years—
A share split breaks the comparison across the period, so we leave it out.
Advertisement
AdSense · Leaderboard 728×90300×250
Balance sheet
USD 18.6M
total assets, end of FY2025
Total assetsUSD 18.6M
EquityUSD -32.2M
CashUSD 8.1M
Current ratio0.38×
Equity funds -173% of total assets.
History
11 fiscal years
Every figure from documents filed with the SEC · USD
Metric
2025
2024
2023
2022
2021
2020
2019
2018
2017
2016
2015
Revenue $B
0.0
·
·
·
·
·
0.0
0.0
0.0
0.0
0.0
Operating income $B
−0.1
−0.1
−0.1
−0.1
−0.1
−0.0
−0.0
−0.0
−0.0
−0.1
−0.0
EBITDA $B
·
·
·
−0.1
−0.1
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
Income tax $B
−0.0
0.0
0.0
0.0
0.0
−0.0
−0.0
−0.0
0.0
0.0
−0.0
Net income $B
−0.1
−0.1
−0.1
−0.1
−0.1
−0.0
−0.0
−0.0
−0.0
−0.1
−0.0
EPS, diluted $
−1.79
−4.06
−4.72
−0.31
−0.35
−0.67
−1.98
−9.74
−1.80
−3.67
−5.43
Dividend / sh $
·
·
·
·
·
·
·
·
·
·
·
Payout %
·
·
·
·
·
·
·
·
·
·
·
ROE %
·
·
·
−990.0
−1430.3
·
·
·
·
·
·
Shares out B
0.05
0.02
0.01
0.23
0.18
0.13
0.03
0.01
0.02
0.02
0.01
Slide the table for earlier years · "·" marks figures not disclosed in the filing for that year.
How we verifyAUDITED
34 of 34
checks passed before publication
EPS recomputationBalance-sheet identityGross profitBalance-sheet liquidity
Every figure was compared against the original statement: 0 failures and 0 presentation gaps.
What we don’t show
We’d rather say what’s missing than fill the gap with an estimate.
P/E rationeeds a market quote — not yet licensed
Market capitalizationneeds a market quote — not yet licensed
Dividend yieldneeds a market quote — not yet licensed
Price-to-bookneeds a market quote — not yet licensed